Technology | September 08, 2014

FDA Clears Low-profile Brain Stent

MicroVention LVIS Stent FDA Clearance July 2014

September 8, 2014 — The U.S, Food and Drug Administration (FDA) has cleared MicroVention Inc.’s Low-Profile Visualized Intraluminal Support Device (LVIS and LVIS Jr.), which is a stent and delivery system used to treat certain brain aneurysms.

The stent is a self-expanding, nickel-titanium (nitinol) single wire braid. The delivery system consists of an introducer and delivery wire and is used to deliver the stent to the aneurysm. The stent keeps the soft platinum coils that are put into the aneurysm from slipping back into the main blood vessel.

The LVIS Device is intended for use with soft platinum coils for the treatment of unruptured, wide-neck brain (intracranial, saccular) aneurysms. The stent serves two functions. One, it supports the coils so they block the aneurysm and two, the stent prevents the coils from slipping back into the main blood vessel.

How it works:

  • Using a guidewire, a small catheter (microcatheter) is advanced into the blood vessel along the aneurysm.
  • The guidewire is removed and the microcatheter remains in place allowing for the proper insertion of the LVIS device.
  • The physician positions the device to be released (deployed) and carefully retracts the microcatheter. The physician then advances the delivery wire allowing the LVIS device to be deployed across the neck of the aneurysm.
  • The stent expands as it exits the microcatheter.
  • After the microcatheter is positioned in the aneurysm, soft platinum coils are delivered into the aneurysm to block the flow of blood into the aneurysm.
  • The LVIS device serves as a support for the coils to prevent them from moving back into the blood vessel.

 

The LVIS Device should not be used in:

  • Patients who cannot take medications that thin the blood and prevent blood clots.
  • Patients with known hypersensitivity to metal, such as nickel-titanium and metal jewelry. Patients with anatomy that does not allow passage or deployment of the LVIS device.
  • Patients with an active bacterial infection.
  • Patients with a pre-existing stent in place at the target aneurysm.

 

For more information: www.accessdata.fda.gov/cdrh_docs/pdf13/H130005a.pdf

 

 

 

 

Related Content

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init